Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's Disease

Sachio Matsushita, Hiroyuki Arai, Nobuyuki Okamura, Tomohiro Ohmori, Keiichi Takasugi, Toshifumi Matsui, Masahiro Maruyama, Takeshi Iwatsubo, Susumu Higuchi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We report an individual who developed Alzheimer's disease (AD) due to a novel presenilin-1 mutation (Alanine→Valine at codon 431). When he first presented, the patient met criteria for mild cognitive impairment but progressed over 16 months to fulfill diagnostic criteria of AD. At his first presentation, he showed widespread metabolic deficits in the posterior cingulate, lateral parietal, posterior parietal, and medial temporal regions on positron emission tomography as well as elevated tau and phospho-tau levels in cerebrospinal fluid (CSF). We suggest that functional neuroimaging and CSF biomarkers can serve as useful predictors of development of AD. Accumulation of pathologic tau isoforms and neuron death occur even in the mildest clinical stages of AD.

Original languageEnglish
Pages (from-to)907-910
Number of pages4
JournalBiological Psychiatry
Volume52
Issue number9
DOIs
Publication statusPublished - 2002 Nov 1

Keywords

  • Alzheimer's disease
  • Cerebral glucose metabolism
  • Cerebrospinal fluid
  • Mild cognitive impairment
  • Phosphorylated tau
  • Presenilin-1 mutation

ASJC Scopus subject areas

  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this